Abstract: A composition for the treatment of Herpes Labialis which contains CTC-96 as the active ingredient is disclosed. Methods for using the composition are also disclosed. The composition may be used as a topical ointment.

Abstract: A method for the therapeutic treatment of psoriasis by the administration of an anti-psoriasis effective amount of Doxivir (CTC-96) is discloses.

Abstract: A method for the therapeutic and prophylactic treatment of subjects infected with the papilloma virus. More specifically, a method of therapeutic treatment of a papilloma virus in a subject by administering an anti-papilloma virus effective amount of CTC-96 to the subject. In addition, a method of prophylactic treatment against a papilloma virus in a subject by administering an anti-papilloma virus effective amount of CTC-96 to the subject to minimize the likelihood of the subject being infected by the papolloma virus.

Abstract: A method of treating an animal having a condition associated with the presence of cyanide in quantities sufficient to cause undesirable symptoms which comprises administering to the subject a compound in an amount effective to alleviate the undesirable symptoms, the compound having the structure: ##STR1## wherein R.sup.1 and R.sup.1' are the same or different and each is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;R.sup.2 and R.sup.2' are the same or different and each is hydrogen, an unbranched alkyl group, a halide or a group having the structure R--C-- ##STR2## wherein R is hydrogen, an alkoxide group, and alkyl group or OH; R.sup.3 and R.sup.3' are the same or different and each is hydrogen or an alkyl group;X and X' are the same or different and each is a water-soluble group having weak to intermediate field strength; andQ.sup.- is a soluble, pharmaceutically acceptable negative ion.

Abstract: A method of treating a subject having a condition associated with the presence of cyanide in quantities sufficient to cause undesirable symptoms which comprises administering to the subject a compound in an amount effective to alleviate the undesirable symptoms, the compound having the structure: ##STR1## wherein R.sup.1 and R.sup.1' are the same or different and each is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;R.sup.2 and R.sup.2' are the same or different and each is hydrogen, an unbranched alkyl group, a halide or a group having the structure ##STR2## wherein R is hydrogen, an alkoxide group, and alkyl group or OH; R.sup.3 and R.sup.3' are the same or different and each is hydrogen or an alkyl group;X and X' are the same or different and each is a water-soluble group having weak to intermediate field strength; andQ.sup.-- is a soluble, pharmaceutically acceptable negative ion.